Transcatheter Mitral and Tricuspid Valve Therapies
Description:... ranscatheter valve therapies have emerged as a viable treatments option for patients deemed high risk for conventional surgery. Whilst transcatheter aortic valve implantation (TAVI) is now established as the standard of care in high-risk aortic stenosis patients, the mitral and tricuspid frontiers have proved to be more challenging. Anatomical heterogeneity, device development, refining patient selection and until recently the absence of randomised data have all been contributing factors. For mitral regurgitation, transcatheter edge to edge repair (TEER) now benefits from positive randomised data along with significant advancements in device technology. Transcatheter mitral valve replacement (TMVR) options are also making rapid progress. More recently, tricuspid regurgitation has become the central focus of the structural heart community having previously been referred to as the “forgotten valve”
Show description